AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%

APTARGROUP, INC.

2025-Q2 EPS reported $2.83 vs consensus $1.58 ▲ beat (+79.2%)

Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.
Pharma core +3% (Injectables +9%, Active Material Science +11%); adj. EBITDA margin 35.4% (+130 bps).
Closures core +7% (food & bev); Beauty core +1% (personal care up, fragrance subdued).
Q3 adj. EPS guidance $1.53-$1.61; includes ~$0.06-$0.07 legal fees for pharma IP litigation.
Returned $100M to shareholders ($70M buybacks, $30M dividends); quarterly dividend $0.45 payable Aug 14.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.